NCT06092879Active, not recruiting
Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France
Scemblix® (Asciminib): Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML-CP in Real World Setting in France
Source: ClinicalTrials.gov · Last updated 29 May 2026
Brief summary (registry, in English)
The purpose of this study is to enhance the knowledge on asciminib treatment in a broader and real-life population by collecting additional data to characterize the treatment patterns of patients treated with asciminib, with a primary objective represented by maintenance on treatment at 12 months.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 201 (actual)
- First submitted
- 16 Oct 2023
- Start date
- 6 Mar 2024
- Primary completion date
- 15 Dec 2026
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Chronic myeloid leukaemia
- NCT number
- NCT06092879
What you commit to
- Study type: Observational
- Participants enrolled: 201
- From 6 Mar 2024 to the primary completion date, 15 Dec 2026
- 48 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient who previously received asciminib treatment,
Other illness
- Patient with known history of T315I mutation,
Other
- Patient with CML in accelerated phase (AP) or blastic phase (BP) at enrolment,
- Patient currently participating to an interventional clinical trial,
- Patient with known contra-indication to asciminib according to the SmPC.
Who the study is looking for
- Patient aged ≥ 18 years at inclusion,
- Patient with Ph+ CML-CP previously treated with two or more TKIs,
- Patient for whom a decision has been taken by the treating physician (investigator) to initiate treatment with asciminib according to his own practice, the drug label / Summary of Product Characteristics (SmPC), and regardless of study participation,
- Patient having given their non objection to participate to the study
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (48)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.